The calcium channel blocker amlodipine and angiotensin ll receptor blocker losartan, with or without hydrochlorothiazide (HCTZ), were compared for the treatment of mild to moderate hypertension in ...

Drugmaker Cipla is seeing a fresh round of changes at the helm, with MK Hamied resigning as Vice Chairman and Non-Executive Director of the company, and his son Kamil Hamied making a re-entry.

Objective: The aim of this study was to compare the antihypertensive efficacy and tolerability of the calcium channel antagonist amlodipine besylate versus the angiotensin II type 1 receptor ...

Telmisartan, amlodipine; 40mg/5mg, 40mg/10mg, 80mg/5mg, 80mg/10mg; tabs. Take once daily. Initial therapy: 40/5mg or 80/5mg; may titrate at 2-week intervals to max 80/10mg. Add-on therapy ...

Cipla Ltd announced the resignation of its Vice Chairman and Non-Executive Director, MK Hamied, citing "age and health" as the reasons. The pharmaceutical giant made the disclosure in a stock ...

Drugmaker Cipla’s management has reiterated that the 2 per cent-odd stake sale by promoters earlier this year was towards philanthropy and social efforts of the company. The recent stake sale ...

Drug major Cipla Ltd said its Vice Chairman and Non-Executive Director MK Hamied has resigned from the company due to "age and health". "Vide letter dated 3rd September 2024, effective close of ...

Cipla has launched an innovative combination of 3 HIV/AIDS drugs, Viraday that needs to be taken just once a day for effective treatment. The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla share price target 2024: Pharma major Cipla is all set to declare quarterly results on Friday, July 26. Ahead of the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This marks Cipla’s third investment in GoApptiv which will be made in a combination of equity shares and compulsorily convertible preference shares In June 2020, Cipla first acquired a 21.85% ...